Literature DB >> 24649084

Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome.

Jin-Hu Yang1, Feng Ren2.   

Abstract

Acute coronary syndrome (ACS) typically occurs when coronary artery disease results in the obstruction of the coronary arteries. Tenascin-C (TNC) and OX40 ligand (OX40L) were shown to be involved in the pathogenesis of atherosclerosis. In this study, 50 healthy controls and 170 patients, including 50 patients with stable angina (SA), 70 with unstable angina and 50 with acute myocardial infarction, were evaluated to assess serum TNC and plasma OX40L levels. The serum TNC levels were measured by a quantitative automated particle-enhanced immunonephelometric assay. ELISA was used to determine the expression levels of OX40L. All the coronary stenoses with a ≥30% diameter reduction were assessed by angiographic coronary stenosis morphology. The patients with ACS exhibited a significant increase in TNC expression levels (39.39±19.80 ng/ml) compared to the levels in the control and SA groups (28.65±12.32 ng/ml, P<0.01 and 31.22±18.92 ng/ml, P<0.05, respectively). The levels of OX40L were also found to be higher in patients with ACS (38.59±15.76 ng/ml) compared to those in the control and SA groups (19.42±11.19 ng/ml, P<0.001 and 21.52±10.30 ng/ml, P<0.001, respectively). The TNC and OX40L levels were positively correlated with each other (r1=0.68; P<0.001) and with fibrinogen levels (r3=0.76 and r4=0.45, respectively; P<0.001). A positive correlation was also observed between the expression of TNC and OX40L and complex coronary stenosis (r5=0.69 and r6=0.55, respectively; P<0.001). We concluded that TNC and OX40L may act synergistically in coronary plaque formation and may be also be involved in the pathogenesis of coronary lesions. Patients with ACS exhibited increased TNC and OX40L expression levels, which may have created a prothrombotic milieu, aggravating the development of atherosclerosis and the instability of atherosclerotic plaques. Therefore, the expression of TNC and OX40L may be a valuable marker for predicting the severity of ACS.

Entities:  

Keywords:  OX40 ligand; acute coronary syndrome; tenascin-C

Year:  2013        PMID: 24649084      PMCID: PMC3917010          DOI: 10.3892/br.2013.195

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  21 in total

1.  Haemodynamic significance of stent lesions compared to native coronary lesions: a myocardial perfusion imaging study.

Authors:  K C Koch; W M Schaefer; K Ersahin; B Nowak; S Krueger; U Buell; P Hanrath; R Hoffmann
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

2.  OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization.

Authors:  Makoto Nakano; Yoshihiro Fukumoto; Kimio Satoh; Yoshitaka Ito; Yutaka Kagaya; Naoto Ishii; Kazuo Sugamura; Hiroaki Shimokawa
Journal:  Cardiovasc Res       Date:  2010-06-27       Impact factor: 10.787

Review 3.  The role of tenascin C in cardiovascular disease.

Authors:  Jonathan Golledge; Paula Clancy; Jane Maguire; Lisa Lincz; Simon Koblar
Journal:  Cardiovasc Res       Date:  2011-06-28       Impact factor: 10.787

Review 4.  Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome.

Authors:  Martin K Reriani; Andreas J Flammer; Abdi Jama; Lilach O Lerman; Amir Lerman
Journal:  Circ J       Date:  2012       Impact factor: 2.993

5.  Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice.

Authors:  Tomoyuki Ueki; Satoshi Murata; Naomi Kitamura; Eiji Mekata; Tohru Tani
Journal:  Mol Med Rep       Date:  2009 Jul-Aug       Impact factor: 2.952

6.  Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.

Authors:  Yoshio Ohno; Miki Izumi; Kunihiko Yoshioka; Makoto Ohori; Hiroyuki Yonou; Masaaki Tachibana
Journal:  Oncol Rep       Date:  2008-09       Impact factor: 3.906

7.  Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor prognosis of esophageal squamous cell carcinoma.

Authors:  Masahisa Ohtsuka; Hirofumi Yamamoto; Ryota Oshiro; Hidekazu Takahashi; Toru Masuzawa; Mamoru Uemura; Naotsugu Haraguchi; Junichi Nishimura; Taishi Hata; Makoto Yamasaki; Ichiro Takemasa; Hiroshi Miyata; Tsunekazu Mizushima; Shuji Takiguchi; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2013-05-24       Impact factor: 5.650

Review 8.  Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome.

Authors:  S Goodacre; P Thokala; C Carroll; J W Stevens; J Leaviss; M Al Khalaf; P Collinson; F Morris; P Evans; J Wang
Journal:  Health Technol Assess       Date:  2013       Impact factor: 4.014

Review 9.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 10.  OX40/OX40 ligand interactions in T-cell regulation and asthma.

Authors:  Davinder Kaur; Christopher Brightling
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

View more
  4 in total

1.  Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome.

Authors:  Murugaiyan Vasanthi; Prashant Shankarrao Adole; Vinay Ramakrishna Pandit; Kolar Vishwanath Vinod
Journal:  J Med Biochem       Date:  2020-10-02       Impact factor: 3.402

2.  The rs3850641 polymorphism of the TNFSF4 gene increases the risk of myocardial infarction in a Chinese Han population.

Authors:  Changqing Lu; Helei Jia; Aiguo Xu
Journal:  Biosci Rep       Date:  2018-07-12       Impact factor: 3.840

Review 3.  Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease.

Authors:  Julius L Decano; Masanori Aikawa
Journal:  Front Cardiovasc Med       Date:  2018-08-03

4.  Evaluation of the serum levels of Mannose binding lectin-2, tenascin-C, and total antioxidant capacity in patients with coronary artery disease.

Authors:  Hamed Mehri; Naser Aslanabadi; Alireza Nourazarian; Behrouz Shademan; Fatemeh Khaki-Khatibi
Journal:  J Clin Lab Anal       Date:  2021-09-07       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.